Any current/future new fundraising through debt or equity?

For FY27, Aether Industries expects additional debt of approximately INR 200-250 crores due to ongoing investments and working capital needs. The company acknowledges that debt will increase gradually and sequentially as capex progresses, not in a lump sum. Recent QIP equity fundraising was completed in Q3 FY26, reducing immediate reliance on equity. Total remaining capex across sites is estimated at INR 1,500-1,600 crores over the next 4 years, suggesting need for continued capital raising, likely through debt. No explicit mention of immediate planned equity fundraising after the QIP

Any current/future capex/capital investment/strategic investment?

FY26 capex was INR 383.8 crores; FY27 capex expected between INR 300-350 crores, primarily for Site 5 and new R&D site. Total remaining capex across announced 3 sites is approximately INR 1500-1600 crores over the next 4 years. Major capex focus: Site 5 commercialization and expansion, Site 1 R&D expansion. Site 5 planned for up to 20 production blocks over ~45-46 acres including newly acquired adjoining land. Investment in expanded world-class R&D infrastructure including large pilot plants and 18 new fume hoods. Site 5’s asset turn target is 1.5 to 1.75. Capex and R&D investments aimed to dr

Future growth expectations in sales/revenue/volumes?

Targeting 70% revenue from CRAMS and CEM and around 30% from Large Scale Manufacturing (LSM) in the next couple of years. Major growth drivers in FY27 include commercialization of Site 5 Phase 1 and ramp-up of Site 3++ and Site 4. Expect sustained elevated prices in LSM for next 2-3 quarters, supporting stable/strong revenues. Site 5 to commercialize three new LSM products priced at $30-$40/kg, expected to contribute meaningfully from FY27. Anticipate revenue growth from existing marquee customers like Milliken and Baker Hughes, supplemented by new projects and sites. Working capital

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth expected from commercialization and ramp-up of Site 5, Site 3++, and Site 4, with strong contributions from CEM and CRAMS segments. Targeting stable EBITDA margins between 29% to 30% and PAT margins around 19% to 20% for FY27. CRAMS and CEM expected to contribute approximately 70% of revenue over next 3-4 years, with LSM around 30%. EBITDA grew 53% YoY in FY26; PAT up 39% YoY, showcasing improving profitability. Sustainable medium-term pricing environment expected, particularly in LSM business, supporting margins. Capex of INR1,500-1,600 crores over next 4 years aimed

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the exact value or volume of the current or expected order book or pending orders. It highlights strong order inflows with a focus on new large-scale manufacturing products at Site 5, with validation batches done and orders already in hand for 3 new products expected by May end or early June. The company has completed over 50 customer and certification audits and added 19 new marquee clients recently. Multiple customers have completed pre-audits for Site 5, indicating strong customer qualification activity and future order potential. The focus is on c

IN US

Sale is live|00:00:00left today

Aether Industries LtdQ1 FY26Chemicals & Petrochemicals

Aether Industries Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,325P/E: 65.2Market Cap: ₹14.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Targeting 70% revenue from CRAMS and CEM and around 30% from Large Scale Manufacturing (LSM) in the next couple of years.
→Major growth drivers in FY27 include commercialization of Site 5 Phase 1 and ramp-up of Site 3++ and Site 4.
→Expect sustained elevated prices in LSM for next 2-3 quarters, supporting stable/strong revenues.
→Site 5 to commercialize three new LSM products priced at $30-$40/kg, expected to contribute meaningfully from FY27.
→Anticipate revenue growth from existing marquee customers like Milliken and Baker Hughes, supplemented by new projects and sites.
→Working capital improvements expected, with days reduced toward ~160 by FY27 end, supporting operational efficiency.
→Capex of INR1,500-1,600 crore over next 4 years focused on expanding manufacturing and R&D capabilities for sustained growth.
→No explicit revenue growth guidance given, but accelerating adoption of new chemistries and production blocks indicates positive volume momentum.

Margin guidance

Category 3

→Revenue growth expected from commercialization and ramp-up of Site 5, Site 3++, and Site 4, with strong contributions from CEM and CRAMS segments.
→Targeting stable EBITDA margins between 29% to 30% and PAT margins around 19% to 20% for FY27.
→CRAMS and CEM expected to contribute approximately 70% of revenue over next 3-4 years, with LSM around 30%.
→EBITDA grew 53% YoY in FY26; PAT up 39% YoY, showcasing improving profitability.
→Sustainable medium-term pricing environment expected, particularly in LSM business, supporting margins.
→Capex of INR1,500-1,600 crores over next 4 years aimed at expansion, with asset turns at Site 5 targeted between 1.5 to 1.75.
→Working capital improvements targeted, aiming for reduction from 179 to around 160 days by FY27, supporting cash flows.
→Management refrains from explicit EPS guidance but emphasizes accelerated growth supported by new product launches and operational scale-up.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→For FY27, Aether Industries expects additional debt of approximately INR 200-250 crores due to ongoing investments and working capital needs.
→The company acknowledges that debt will increase gradually and sequentially as capex progresses, not in a lump sum.
→Recent QIP equity fundraising was completed in Q3 FY26, reducing immediate reliance on equity.
→Total remaining capex across sites is estimated at INR 1,500-1,600 crores over the next 4 years, suggesting need for continued capital raising, likely through debt.
→No explicit mention of immediate planned equity fundraising after the QIP in Q3 FY26.
→The company is focusing on disciplined execution and operating cash flow management alongside raising funds for growth.

Order book

Yes

→The transcript does not explicitly mention the exact value or volume of the current or expected order book or pending orders.
→It highlights strong order inflows with a focus on new large-scale manufacturing products at Site 5, with validation batches done and orders already in hand for 3 new products expected by May end or early June.
→The company has completed over 50 customer and certification audits and added 19 new marquee clients recently.
→Multiple customers have completed pre-audits for Site 5, indicating strong customer qualification activity and future order potential.
→The focus is on converting opportunities into execution with a growing customer base and expanding capacity at multiple sites.
→Continuous order inflows from key customers such as Baker Hughes confirmed, with steady demand and no cancellations or delays mentioned.
→Overall, order momentum is strong with increasing mix from CRAMS and CEM contributing to anticipated growth.

Capex plans

Yes

→FY26 capex was INR 383.8 crores; FY27 capex expected between INR 300-350 crores, primarily for Site 5 and new R&D site.
→Total remaining capex across announced 3 sites is approximately INR 1500-1600 crores over the next 4 years.
→Major capex focus: Site 5 commercialization and expansion, Site 1 R&D expansion.
→Site 5 planned for up to 20 production blocks over ~45-46 acres including newly acquired adjoining land.
→Investment in expanded world-class R&D infrastructure including large pilot plants and 18 new fume hoods.
→Site 5’s asset turn target is 1.5 to 1.75.
→Capex and R&D investments aimed to drive transition to 70% revenue from CRAMS and CEM models by FY30.
→Additional debt of INR 200-250 crores expected in FY27 to support capex.
→Expansion of senior leadership team focused on technology and business development to capitalize on opportunities.

How does Aether Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aether Industries Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aether Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio